Vodič za dijagnostikovanje i lečenje lipidskih poremećaja

83. Rader DJ, Rosas S. Management of selected lipid abnormalities: hypertriglyceridemia, low HDL
cholesterol, lipoprotein(a), in thyroid and renal diseases, and posttransplantation. Med Clin North
Am 2000;84:43–61.
84. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation
in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
85. Robins SJ, Collins D, et al. VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels
with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585–1591.
86. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial
infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial
investigators. N Engl J Med 1996;335:1001–1009.
87. Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, Furberg CD, Braunwald
E. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics
and enhaced role for HDL-cholesterol and triglycerides as risk factors. Circulation
2002;105(12):1424–8.
88. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular
disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical
trials. Am Heart J 2007;154(5):943–53.
89. Santinga JT, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term
treatment of elderly patients with hypercholesterolemia. Am J Med 1994;96:509–515.
90. Seed M, Jones L, Mc Laren M, et al. The effect of hormone replacement therapy and route of
administration on selected cardiovascular risk factors in postmenopausal women in Jacotot B,
Mathe D, Fruchart J-C (eds). Atherosclerosis XI. Execerpta Medica. Elsevier, Amsterdam–Singapore,
1998;831–836.
91. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular
disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–1630.
92. Smith, CA, Allen, J., Blair, SN,, et all AHA/ACC Guidelines for Secondary Prevention for Patients
with Coronary and Other Atherosclerotic Vascular Disease: 2006 Update, J Am Coll Cardiol
2006;47:2130–2139.
93. Stamler J, Wenthworth D, Neaton JD. Is relationship between serum cholesterol risk death from
coronary heart disease continuous and graded. JAMA 1986;256:2823–8.
94. Steiner G. Fibrates in the metabolic syndrome and diabetes. Endocrinol Metab Clin N Am
2004;33:545–555.
95. Strong JP: The Natural History of Atherosclerosis in childhood, Hyperlipidemia in childhood
and the development of atherosclerosis. Ann NY Acad Sci 1991;623:9–15.
96. Study Group, European Atherosclerosis Society. The recognition and management of hyperlipidaemia
in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J
1988;9:571–600.
97. Takasaki Y: Serum Lipid Levels and Factors Affecting Atherogenic Index in Japanese Children.
J Physiol Anthropol Apll Hum Sci 2005;24:511–515.
98. Taylor AJ, Sullenberger LE, et al. Arterial Biology for the Investigation of the Treatment Effects
of Reduction Colesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release
niacin on atherosclerosis progression in secondary prevention patients treated with statins.
Circulation 2004;110:3512–3517.
99. The Expert Panel. The Third Report of the National Education Program (NCEP), Expert Panel
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III). Final report. Circulation 2002;106(25):3143–421.
100. Tonstad S, Knudtzon J, Sivertsen M, et al. Efficacy and safety of cholestyramine therapy in peripubertal
and prepubertal children with familial hypercholesterolemia. J Pediatr 1996;129:42–49.
47